Statera BioPharma (STU:7CB) OCF Yield %: 0.00 (As of Jun. 30, 2026)


What is Statera BioPharma OCF Yield %?

Statera BioPharma STU:7CB 20 OCF Yield % is 0.00 as of Jun. 30, 2026. GuruFocus rates STU:7CB with a GF Score™ of 20/100. The stock has 1 warning sign investors should review.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Statera BioPharma's Trailing 12-Month Cash Flow from Operations is €-10.90 Mil, and Market Cap is €0.01 Mil. Therefore, Statera BioPharma's OCF Yield % for today is 0.00%.

The historical rank and industry rank for Statera BioPharma's OCF Yield % or its related term are showing as below:


STU:7CB's OCF Yield % is not ranked *
in the Biotechnology industry.
Industry Median: -8.185
* Ranked among companies with meaningful OCF Yield % only.

Statera BioPharma's OCF Margin % for the quarter that ended in Sep. 2022 was %.

Statera BioPharma OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Statera BioPharma OCF Yield % Related Terms

Statera BioPharma OCF Yield % Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma OCF Yield % Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
OCF Yield %
0.00 0.00 0.00

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Statera BioPharma OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Statera BioPharma's OCF Yield % for the fiscal year that ended in Dec. 2021 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-24.951 / 0
=N/A%

Statera BioPharma's annualized OCF Yield % for the quarter that ended in Sep. 2022 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-0.81 * 4 / 0
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of 0.00 mean?
Statera BioPharma (STU:7CB) has a OCF Yield % of 0.00 as of Jun. 30, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's OCF Yield % too high?
Statera BioPharma's current OCF Yield % is 0.00. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's OCF Yield % compare to NRBO and PALI?
Statera BioPharma's OCF Yield % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current OCF Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STU:7CB) has a current OCF Yield % of 0.00. The current OCF Yield % is 0.00. Statera BioPharma's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Statera BioPharma (STU:7CB), the current OCF Yield % is 0.00 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.